Insider Buying: Aptevo Therapeutics Inc (NASDAQ:APVO) Director Buys $16,081.15 in Stock

Aptevo Therapeutics Inc (NASDAQ:APVO) Director Fuad El-Hibri purchased 18,919 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were acquired at an average price of $0.85 per share, for a total transaction of $16,081.15. Following the purchase, the director now directly owns 843,455 shares in the company, valued at $716,936.75. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

APVO opened at $0.86 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 2.91 and a current ratio of 3.15. Aptevo Therapeutics Inc has a fifty-two week low of $0.67 and a fifty-two week high of $5.80. The company’s fifty day moving average price is $0.83.

Aptevo Therapeutics (NASDAQ:APVO) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.44). Aptevo Therapeutics had a negative net margin of 199.24% and a negative return on equity of 122.33%. The company had revenue of $7.02 million for the quarter, compared to analysts’ expectations of $6.30 million. As a group, equities analysts expect that Aptevo Therapeutics Inc will post -1.4 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP lifted its stake in shares of Aptevo Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock valued at $1,831,000 after buying an additional 16,482 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of Aptevo Therapeutics by 251.7% during the 4th quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock valued at $419,000 after buying an additional 236,300 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Aptevo Therapeutics during the 1st quarter valued at $33,000. Institutional investors own 36.37% of the company’s stock.

Several research analysts have recently weighed in on the stock. Roth Capital reiterated a “buy” rating on shares of Resverlogix in a research note on Thursday, May 23rd. Zacks Investment Research cut shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Piper Jaffray Companies lifted their target price on shares of Aptevo Therapeutics from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, April 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $7.88.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Featured Story: Analyzing a company’s cash flow statement

Insider Buying and Selling by Quarter for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.